Figure 2.
Figure 2. Ex vivo bioassay for FLT3 inhibition. The immunoblot on the left was derived from peripheral blood leukemia cells isolated from a patient before and 1 hour after the initial dose of CEP-701. The blot on the right was obtained from TF/ITD cells exposed to the plasma from the same patient at the same time point. FLT3 was immunoprecipitated from detergent extracts of leukemia cells, resolved with SDS-PAGE, and transferred to PVDF membranes. The phosphorylated state of the receptor (upper bands, P-FLT3) was determined by immunoblotting with an antiphosphotyrosine antibody. Membranes were then stripped and reprobed with anti-FLT3 antibody to assess total FLT3 protein (lower bands, FLT3). Densitometric analysis of phosphorylated FLT3, normalized for the amount of total FLT3, is displayed graphically with columns.

Ex vivo bioassay for FLT3 inhibition. The immunoblot on the left was derived from peripheral blood leukemia cells isolated from a patient before and 1 hour after the initial dose of CEP-701. The blot on the right was obtained from TF/ITD cells exposed to the plasma from the same patient at the same time point. FLT3 was immunoprecipitated from detergent extracts of leukemia cells, resolved with SDS-PAGE, and transferred to PVDF membranes. The phosphorylated state of the receptor (upper bands, P-FLT3) was determined by immunoblotting with an antiphosphotyrosine antibody. Membranes were then stripped and reprobed with anti-FLT3 antibody to assess total FLT3 protein (lower bands, FLT3). Densitometric analysis of phosphorylated FLT3, normalized for the amount of total FLT3, is displayed graphically with columns.

Close Modal

or Create an Account

Close Modal
Close Modal